Literature DB >> 3373343

Intestinal oxalate-degrading bacteria reduce oxalate absorption and toxicity in guinea pigs.

R A Argenzio1, J A Liacos, M J Allison.   

Abstract

Previous studies have provided evidence that an anaerobic bacterium, which degrades dietary oxalate to CO2 and formate, is present in colonic contents of a number of herbivorous species, laboratory rodents and humans. The present study examines the possibility that these bacteria degrade significant amounts of oxalate and can influence colonic oxalate absorption. Guinea pigs adapted to a diet containing 2% sodium oxalate or fed a normal diet were challenged with 67, 135, 170 or 200 mg of sodium oxalate containing 0.5 microCi of [14C]oxalate, which was injected into the cecum. Adapted animals excreted approximately 2% of the 14C in the urine, regardless of the dose, whereas unadapted animals excreted significantly higher amounts in the urine at the two lower doses and died at the two higher doses. Conversely, antibiotic treatment of adapted guinea pigs reduced the ability of their cecal flora to degrade oxalate, and a correspondingly greater percentage of an injected oxalate load was excreted in the urine. Oxalate degradation rates in cecal fluid were depressed by the secondary bile salt deoxycholate, and in vitro studies with pure isolates of guinea pig and human strains of oxalate degraders confirmed that these bacteria were highly sensitive to low concentrations of deoxycholate. Results indicate that these bacteria may be important in preventing excess absorption of oxalate and raise the possibility that the hyperoxaluria associated with bile salt malabsorption of ileal disease in part may be due to suppression of these bacteria by the bile salts.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3373343     DOI: 10.1093/jn/118.6.787

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  17 in total

1.  Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation.

Authors:  John C Lieske; William J Tremaine; Claudio De Simone; Helen M O'Connor; Xujian Li; Eric J Bergstralh; David S Goldfarb
Journal:  Kidney Int       Date:  2010-08-25       Impact factor: 10.612

Review 2.  Intestinal transport of an obdurate anion: oxalate.

Authors:  Marguerite Hatch; Robert W Freel
Journal:  Urol Res       Date:  2004-11-25

3.  Probiotics for prevention of urinary stones.

Authors:  John C Lieske
Journal:  Ann Transl Med       Date:  2017-01

Review 4.  The potential for nutritional components of food items used for enrichment of research animals to act as confounding variables in toxicology studies.

Authors:  Dale M Cooper
Journal:  Lab Anim (NY)       Date:  2015-06       Impact factor: 12.625

5.  Oxalobacter formigenes Colonization and Oxalate Dynamics in a Mouse Model.

Authors:  Xingsheng Li; Melissa L Ellis; John Knight
Journal:  Appl Environ Microbiol       Date:  2015-05-15       Impact factor: 4.792

6.  Oxalobacter formigenes reduce the risk of kidney stones in patients exposed to oral antibiotics: a case-control study.

Authors:  Yamuna Ravikumar; Rukaiah Fatma Begum; Ramaiyan Velmurugan
Journal:  Int Urol Nephrol       Date:  2020-09-02       Impact factor: 2.370

Review 7.  Management of patients with a short bowel.

Authors:  J M Nightingale
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

8.  Probiotic properties of Oxalobacter formigenes: an in vitro examination.

Authors:  Melissa L Ellis; Alexander E Dowell; Xingsheng Li; John Knight
Journal:  Arch Microbiol       Date:  2016-07-23       Impact factor: 2.552

9.  Oxalobacter formigenes and its potential role in human health.

Authors:  Sylvia H Duncan; Anthony J Richardson; Poonam Kaul; Ross P Holmes; Milton J Allison; Colin S Stewart
Journal:  Appl Environ Microbiol       Date:  2002-08       Impact factor: 4.792

10.  Nephrolithiasis after bariatric surgery for obesity.

Authors:  John C Lieske; Rajiv Kumar; Maria L Collazo-Clavell
Journal:  Semin Nephrol       Date:  2008-03       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.